New Diabetes Technology to Watch for in 2020
Jan 6, 2020 10:57:58 GMT -5
factspls88, prcgorman2, and 9 more like this
Post by harryx1 on Jan 6, 2020 10:57:58 GMT -5
New Diabetes Technology to Watch for in 2020
www.healthline.com/diabetesmine/diabetes-tech-spectations-2020
Bluetooth Connectivity for Afrezza
Hello, BluHale! MannKind Corp., makers of Afrezza inhaled insulin, tell us they’ll be launching a BluHale Pro in 2020, specifically for healthcare providers. This add-on adapter will allow the Afrezza inhaler device to feature connectivity.
While it won’t include dosing data initially, the BluHale Pro will monitor inhalation technique for doctors to use in training new patients. The unit is compatible with Android, iPhone and Microsoft devices. It flashes a green light if the Afrezza is inhaled properly and a red light if not. Doctors can view the tracked data on these instances and then offer their patients advice on how to best use Afrezza. BluHale will eventually be able to track and share dosing data as well.
MannKind’s CEO Michael Castagna says they also plan to start their Phase 3 pediatric trial soon, which is the last step before pursuing regulatory OK for Afrezza use in children.
www.healthline.com/diabetesmine/diabetes-tech-spectations-2020
Bluetooth Connectivity for Afrezza
Hello, BluHale! MannKind Corp., makers of Afrezza inhaled insulin, tell us they’ll be launching a BluHale Pro in 2020, specifically for healthcare providers. This add-on adapter will allow the Afrezza inhaler device to feature connectivity.
While it won’t include dosing data initially, the BluHale Pro will monitor inhalation technique for doctors to use in training new patients. The unit is compatible with Android, iPhone and Microsoft devices. It flashes a green light if the Afrezza is inhaled properly and a red light if not. Doctors can view the tracked data on these instances and then offer their patients advice on how to best use Afrezza. BluHale will eventually be able to track and share dosing data as well.
MannKind’s CEO Michael Castagna says they also plan to start their Phase 3 pediatric trial soon, which is the last step before pursuing regulatory OK for Afrezza use in children.
all 3 of my bio stocks!